JP2019500894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500894A5 JP2019500894A5 JP2018543279A JP2018543279A JP2019500894A5 JP 2019500894 A5 JP2019500894 A5 JP 2019500894A5 JP 2018543279 A JP2018543279 A JP 2018543279A JP 2018543279 A JP2018543279 A JP 2018543279A JP 2019500894 A5 JP2019500894 A5 JP 2019500894A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- variant
- seq
- domain
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021133074A JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562251052P | 2015-11-04 | 2015-11-04 | |
| US62/251,052 | 2015-11-04 | ||
| PCT/US2016/060724 WO2017079694A2 (en) | 2015-11-04 | 2016-11-04 | Chimeric antigen receptors targeting her2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021133074A Division JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500894A JP2019500894A (ja) | 2019-01-17 |
| JP2019500894A5 true JP2019500894A5 (https=) | 2019-12-19 |
| JP6932709B2 JP6932709B2 (ja) | 2021-09-08 |
Family
ID=58662864
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543279A Expired - Fee Related JP6932709B2 (ja) | 2015-11-04 | 2016-11-04 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
| JP2021133074A Active JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
| JP2023065384A Withdrawn JP2023100653A (ja) | 2015-11-04 | 2023-04-13 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021133074A Active JP7264954B2 (ja) | 2015-11-04 | 2021-08-18 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
| JP2023065384A Withdrawn JP2023100653A (ja) | 2015-11-04 | 2023-04-13 | Ｈｅｒ２を標的とするキメラ抗原受容体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11197919B2 (https=) |
| EP (2) | EP4074731A1 (https=) |
| JP (3) | JP6932709B2 (https=) |
| KR (1) | KR20180083874A (https=) |
| CN (2) | CN116063574A (https=) |
| AU (2) | AU2016349722A1 (https=) |
| BR (1) | BR112018009129A2 (https=) |
| CA (1) | CA3004306A1 (https=) |
| ES (1) | ES2909973T3 (https=) |
| IL (2) | IL259120B (https=) |
| MX (2) | MX2018005674A (https=) |
| RU (1) | RU2753695C2 (https=) |
| WO (1) | WO2017079694A2 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| EP4074731A1 (en) * | 2015-11-04 | 2022-10-19 | City of Hope | Chimeric antigen receptors targeting her2 |
| ES2879700T3 (es) * | 2016-02-05 | 2021-11-22 | Hope City | Administración de células T genomanipuladas para el tratamiento de cánceres en el sistema nervioso central |
| WO2018102761A1 (en) * | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
| WO2018124766A2 (ko) | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| IL268755B2 (en) | 2017-02-20 | 2025-12-01 | Dragonfly Therapeutics Inc | Proteins that bind her2, nkg2d, and cd16 |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
| US12116417B2 (en) * | 2017-11-14 | 2024-10-15 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN109608547B (zh) * | 2017-12-29 | 2022-03-15 | 郑州大学第一附属医院 | 表达Her2的嵌合抗原受体、慢病毒表达载体及其应用 |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| EA202091887A1 (ru) | 2018-02-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры |
| EP3749686A4 (en) * | 2018-02-09 | 2022-01-05 | National University of Singapore | ADHESION RECEPTOR CONSTRUCTS AND THEIR USES IN IMMUNOTHERAPY WITH NATURAL KILLER CELLS |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| KR102795055B1 (ko) | 2018-02-11 | 2025-04-11 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Car-t 세포 및 자가면역 질환 |
| SG10201801219VA (en) | 2018-02-13 | 2019-09-27 | Agency Science Tech & Res | Anti-HER2 Antibodies |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| WO2019222579A1 (en) * | 2018-05-17 | 2019-11-21 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with myd88 and cd40 costimulatory domains |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| US12378318B2 (en) | 2018-08-08 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US20230065784A1 (en) | 2019-03-21 | 2023-03-02 | City Of Hope | Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl |
| CA3139319A1 (en) * | 2019-05-07 | 2020-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| BR112022014568A2 (pt) * | 2020-01-23 | 2022-09-27 | Exuma Biotech Corp | Receptores de antígeno quiméricos contra her2 e métodos de uso dos mesmos |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| IL298326A (en) * | 2020-05-22 | 2023-01-01 | Gc Cell Corp | Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN112481284B (zh) * | 2020-12-07 | 2023-07-25 | 深圳瑞吉生物科技有限公司 | 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用 |
| WO2022187182A1 (en) * | 2021-03-02 | 2022-09-09 | The Trustees Of The University Of Pennsylvania | Targeting t regulatory cells to islet cells to stall or reverse type 1 diabetes |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| WO2022212525A2 (en) | 2021-03-30 | 2022-10-06 | City Of Hope | Car t cell therapy and ifn gamma |
| CN117642510A (zh) * | 2021-07-01 | 2024-03-01 | 宁波茂行生物医药科技有限公司 | 靶向her2的通用型car-t细胞及其制备方法 |
| CA3226798A1 (en) | 2021-07-29 | 2023-02-02 | James MATTHAEI | Synovial extracellular matrix-specific chimeric antigen receptor for targeting regulatory t cells to treat autoimmune diseases |
| US20240374722A1 (en) * | 2021-08-24 | 2024-11-14 | Cells & Genes Biotech (Shanghai) Co., Ltd | T cell product and use thereof |
| CN116023491A (zh) | 2021-10-25 | 2023-04-28 | 江苏众红生物工程创药研究院有限公司 | 抗cd26抗体及其应用 |
| WO2023172514A1 (en) * | 2022-03-07 | 2023-09-14 | Catamaran Bio, Inc. | Engineered immune cell therapeutics targeted to her2 and methods of use thereof |
| CA3245584A1 (en) | 2022-03-10 | 2023-09-14 | City Of Hope | IL-12 Bound to the Membrane for Cellular Immunotherapy |
| CA3247010A1 (en) * | 2022-04-08 | 2023-10-12 | Ono Pharmaceutical Co., Ltd. | CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING |
| EP4504914A4 (en) * | 2022-04-08 | 2026-04-29 | Fate Therapeutics Inc | Cells having solid tumor targeting backbone and use thereof |
| CN114805584B (zh) * | 2022-06-30 | 2022-09-09 | 上海优替济生生物医药有限公司 | 抗原结合蛋白及其用途 |
| AU2024264153A1 (en) | 2023-04-27 | 2025-11-13 | Vanudis GmbH | Coreceptor chimeric antigen receptor |
| US20250146017A1 (en) | 2023-11-06 | 2025-05-08 | City Of Hope | Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers |
| CN117924518B (zh) * | 2024-01-05 | 2025-08-22 | 苏州艾凯利元生物科技有限公司 | 用于nk细胞的嵌合抗原受体及工程化的nk细胞 |
| WO2025184170A1 (en) | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Methods and compositions for improving t cell function in an immunosuppressive environment |
| WO2025217175A1 (en) * | 2024-04-08 | 2025-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Engineering immune cells to migrate to, infiltrate, persist, and expand in solid tumors |
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE399796T1 (de) * | 1999-04-09 | 2008-07-15 | Univ Zuerich | Verfahren zur stabilisierung von chimären immunoglobulinen oder immunoglobulinfragmenten und stabilisiertes anti-egp-2-scfv-fragment |
| KR20140032004A (ko) * | 2004-07-22 | 2014-03-13 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| US8933197B2 (en) * | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| DK2496698T3 (en) * | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| WO2011137245A2 (en) | 2010-04-30 | 2011-11-03 | Esperance Pharmaceuticals, Inc. | Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
| US8491908B2 (en) | 2010-06-01 | 2013-07-23 | Canon Kabushiki Kaisha | Composite particle, contrast agent for photoacoustic imaging, and method for producing the composite particle |
| WO2012050374A2 (en) | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| PL2718322T3 (pl) * | 2011-06-06 | 2019-07-31 | Novo Nordisk A/S | Lecznicze przeciwciała |
| CA2881981A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| EP3456734B1 (en) * | 2012-10-04 | 2022-01-05 | Research Development Foundation | Serine protease molecules and therapies |
| WO2014055657A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2013337926B2 (en) | 2012-10-30 | 2017-12-21 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| WO2014182970A1 (en) * | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
| CN105940102B (zh) * | 2013-08-26 | 2020-02-18 | 海瑞克·亚柏坎 | 抗cd30嵌合抗原受体及其用途 |
| US20160333108A1 (en) | 2014-01-13 | 2016-11-17 | Stephen J. Forman | CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE |
| KR20160145802A (ko) * | 2014-04-23 | 2016-12-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법 |
| EP4074731A1 (en) * | 2015-11-04 | 2022-10-19 | City of Hope | Chimeric antigen receptors targeting her2 |
-
2016
- 2016-11-04 EP EP22157943.6A patent/EP4074731A1/en not_active Withdrawn
- 2016-11-04 ES ES16863128T patent/ES2909973T3/es active Active
- 2016-11-04 KR KR1020187015769A patent/KR20180083874A/ko not_active Ceased
- 2016-11-04 MX MX2018005674A patent/MX2018005674A/es unknown
- 2016-11-04 EP EP16863128.1A patent/EP3371227B8/en active Active
- 2016-11-04 US US15/773,754 patent/US11197919B2/en active Active
- 2016-11-04 RU RU2018118817A patent/RU2753695C2/ru active
- 2016-11-04 BR BR112018009129-4A patent/BR112018009129A2/pt not_active IP Right Cessation
- 2016-11-04 CN CN202211409883.2A patent/CN116063574A/zh active Pending
- 2016-11-04 CA CA3004306A patent/CA3004306A1/en active Pending
- 2016-11-04 CN CN201680076412.0A patent/CN108779174B/zh not_active Expired - Fee Related
- 2016-11-04 WO PCT/US2016/060724 patent/WO2017079694A2/en not_active Ceased
- 2016-11-04 JP JP2018543279A patent/JP6932709B2/ja not_active Expired - Fee Related
- 2016-11-04 AU AU2016349722A patent/AU2016349722A1/en not_active Abandoned
-
2018
- 2018-05-03 IL IL259120A patent/IL259120B/en unknown
- 2018-05-04 MX MX2022013498A patent/MX2022013498A/es unknown
-
2021
- 2021-08-18 JP JP2021133074A patent/JP7264954B2/ja active Active
- 2021-12-06 US US17/543,148 patent/US20220265796A1/en not_active Abandoned
-
2022
- 2022-01-10 AU AU2022200116A patent/AU2022200116A1/en not_active Abandoned
- 2022-04-13 IL IL292222A patent/IL292222A/en unknown
-
2023
- 2023-04-13 JP JP2023065384A patent/JP2023100653A/ja not_active Withdrawn
-
2024
- 2024-10-18 US US18/919,692 patent/US20250333471A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500894A5 (https=) | ||
| RU2018118817A (ru) | Химерные рецепторы антигена, нацеленные на her2 | |
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| IL292650A (en) | Chimeric antigen receptor T cells target il13ra2 | |
| TWI710572B (zh) | 改善配對的ｔ細胞受體 | |
| JP2017537627A5 (https=) | ||
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| ES2833162T3 (es) | Receptor de antígeno quimérico y su uso | |
| RU2685479C2 (ru) | Химерный антигенный рецептор | |
| CN104177499B (zh) | 一种嵌合抗原受体、编码基因、表达载体及其应用 | |
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| ES2959480T3 (es) | Acoplador de células T - antígeno trifuncional y métodos y usos del mismo | |
| ES2848478T3 (es) | Receptores quiméricos para antígenos y usos de estos | |
| JP2015518479A5 (https=) | ||
| JP2017500869A5 (https=) | ||
| JP2019528078A (ja) | 細胞治療のための構造的に活性なサイトカイン受容体 | |
| RU2016143384A (ru) | Трансгенные генетические метки и способы применения | |
| JP2016520074A5 (https=) | ||
| JP2018509163A5 (https=) | ||
| CN108779160A (zh) | 施用工程化t细胞以治疗中枢神经系统中的癌症 | |
| JP2016538855A5 (https=) | ||
| JP2017538401A5 (https=) | ||
| JPWO2020014366A5 (https=) | ||
| JP2019512251A5 (https=) | ||
| CN105802909A (zh) | 具有her2特异性tcr的t细胞制备物及其用途 |